Masanori Numazaki

Title: Masanori Numazaki: Innovator in Monoclonal Antibody Development

Introduction

Masanori Numazaki is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer treatment and immunotherapy.

Latest Patents

Masanori Numazaki holds a patent for an anti-CD20 monoclonal antibody. This murine anti-CD20 monoclonal antibody exhibits cell growth inhibitory activities, including apoptosis against human CD20 antigen-expressing cells in culture. The antibody is designed to be incorporated into chimeric anti-CD20 monoclonal antibodies, which fuse the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody with the constant regions of human immunoglobulin. Additionally, a humanized version of the anti-CD20 monoclonal antibody is described, which includes all variable region CDRs of both the heavy and light chains of the antibody, along with an amino acid sequence of human immunoglobulin. The nucleotide sequence encoding this chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.

Career Highlights

Masanori Numazaki has made significant strides in his career, particularly through his work at Biomedics Inc. His innovative research has positioned him as a key figure in the biotechnology sector, focusing on therapeutic applications of monoclonal antibodies.

Collaborations

Throughout his career, Masanori has collaborated with notable colleagues, including Tetsuo Nakamura and Sadakazu Usuda. These collaborations have further enhanced the development and application of his inventions in the field.

Conclusion

Masanori Numazaki's contributions to the field of monoclonal antibodies represent a significant advancement in biotechnology. His innovative work continues to influence cancer treatment and immunotherapy, showcasing the importance of research and collaboration in scientific progress.